MX2023005759A - Composiciones y metodos para suministro de farmaco dermico profundo. - Google Patents
Composiciones y metodos para suministro de farmaco dermico profundo.Info
- Publication number
- MX2023005759A MX2023005759A MX2023005759A MX2023005759A MX2023005759A MX 2023005759 A MX2023005759 A MX 2023005759A MX 2023005759 A MX2023005759 A MX 2023005759A MX 2023005759 A MX2023005759 A MX 2023005759A MX 2023005759 A MX2023005759 A MX 2023005759A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- drug delivery
- deep dermal
- dermal drug
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 title 1
- 230000002500 effect on skin Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- DNBCBAXDWNDRNO-FOSCPWQOSA-N (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide Chemical compound COC1=NSC(NC(=O)N2C[C@H]3CC(C[C@H]3C2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 DNBCBAXDWNDRNO-FOSCPWQOSA-N 0.000 abstract 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 abstract 1
- 229940086555 cyclomethicone Drugs 0.000 abstract 1
- 229940008099 dimethicone Drugs 0.000 abstract 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 abstract 1
- 239000004205 dimethyl polysiloxane Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940126397 ivarmacitinib Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 abstract 1
- 229920001296 polysiloxane Polymers 0.000 abstract 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 1
- 229960002256 spironolactone Drugs 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones farmacéuticas para la administración tópica de un fármaco a la unidad pilosebácea y métodos para la administración de las mismas; como se describe aquí, los inventores de la presente invención han hecho el sorprendente descubrimiento de que las composiciones farmacéuticas que comprenden pequeñas partículas de un ingrediente farmacéutico activo y una silicona, tal como dimeticona o ciclometicona, pueden administrarse a la unidad pilosebácea; la composición farmacéutica puede comprender SHR0302 o espironolactona como ingrediente farmacéutico activo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063114887P | 2020-11-17 | 2020-11-17 | |
| US202163221349P | 2021-07-13 | 2021-07-13 | |
| PCT/US2021/059479 WO2022108911A1 (en) | 2020-11-17 | 2021-11-16 | Compositions and methods for deep dermal drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005759A true MX2023005759A (es) | 2023-05-29 |
Family
ID=78844577
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005763A MX2023005763A (es) | 2020-11-17 | 2021-11-16 | Composiciones y metodos para la administracion dermica profunda de farmacos. |
| MX2023005759A MX2023005759A (es) | 2020-11-17 | 2021-11-16 | Composiciones y metodos para suministro de farmaco dermico profundo. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005763A MX2023005763A (es) | 2020-11-17 | 2021-11-16 | Composiciones y metodos para la administracion dermica profunda de farmacos. |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US20220152033A1 (es) |
| EP (2) | EP4247491A1 (es) |
| JP (3) | JP2023550364A (es) |
| KR (2) | KR20230144002A (es) |
| AU (2) | AU2021381899A1 (es) |
| CA (2) | CA3198046A1 (es) |
| IL (2) | IL302867A (es) |
| MX (2) | MX2023005763A (es) |
| WO (2) | WO2022108913A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023086471A1 (en) * | 2021-11-11 | 2023-05-19 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of spironolactone for deep dermal drug delivery |
| US12161643B2 (en) * | 2021-12-15 | 2024-12-10 | Arcutis Biotherapeutics, Inc. | Stable formulations of SHR0302 |
| WO2024165036A1 (zh) * | 2023-02-07 | 2024-08-15 | 瑞石生物医药有限公司 | 一种局部给药的药物组合物、其制备方法及应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3013012A (en) | 1960-12-22 | 1961-12-12 | Searle & Co | Alkanoylthio-17alpha-carboxyethyl-17beta-hydroxyandrosten-3-one lactones |
| US4837211A (en) | 1987-04-06 | 1989-06-06 | Carolina Medical Products, Inc. | Spironolactone composition |
| FR2787322B1 (fr) * | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie |
| BR0215979A (pt) | 2002-12-13 | 2005-11-01 | Jagotec Ag | Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica |
| US9114077B2 (en) | 2006-11-17 | 2015-08-25 | Abbvie Deutschland Gmbh & Co Kg | Nanocrystals for use in topical cosmetic formulations and method of production thereof |
| US9211258B2 (en) * | 2010-03-10 | 2015-12-15 | Lupin Limited | Rifaximin ready-to-use suspension |
| US9636353B2 (en) | 2010-10-21 | 2017-05-02 | Cadila Healthcare Limited | Method for treatment of acne using pharmaceutical compositions of clindamycin and adapalene |
| US9713590B2 (en) | 2011-07-28 | 2017-07-25 | Cadila Healthcare Limited | Method for treatment of pain and inflammation |
| WO2013091539A1 (zh) | 2011-12-21 | 2013-06-27 | 江苏恒瑞医药股份有限公司 | 吡咯并六元杂芳环类衍生物、其制备方法及其在医药上的应用 |
| WO2014194741A1 (zh) | 2013-06-07 | 2014-12-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐及其制备方法 |
| GB201402448D0 (en) * | 2014-02-12 | 2014-03-26 | Buzzz Pharmaceuticals Ltd | Novel formulation |
| CN105566327A (zh) | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
| HRP20192030T1 (hr) | 2014-11-05 | 2020-02-07 | Jiangsu Hengrui Medicine Co., Ltd. | Kristalni oblik bisulfatnog inhibitora jak kinaze i postupak njegovog dobivanja |
| WO2016135754A1 (en) | 2015-02-25 | 2016-09-01 | Sun Pharma Advanced Research Company Ltd | Nanoparticulate composition |
| RU2017134566A (ru) * | 2015-03-23 | 2019-04-05 | Байофармкс, Инк. | Фармацевтическая тетрациклиновая композиция для дерматологического применения |
| US10792293B2 (en) * | 2015-07-31 | 2020-10-06 | Hamidreza Kelidari | Topical nanodrug formulation |
| KR102742522B1 (ko) | 2015-09-16 | 2024-12-12 | 디에프비 소리아, 엘엘씨 | 약물 나노입자 전달체 및 이의 제조방법 |
| EP3417861B1 (en) | 2016-02-19 | 2020-09-23 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof |
| SG11202001720RA (en) * | 2017-07-26 | 2020-03-30 | Ftf Pharma Private Ltd | Liquid dosage forms of imatinib |
| WO2019040706A1 (en) * | 2017-08-24 | 2019-02-28 | Aclaris Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING VITILIGO |
| WO2019096303A1 (zh) * | 2017-11-20 | 2019-05-23 | 江苏恒瑞医药股份有限公司 | 一种局部给药的药物组合物及其制备方法 |
| CA3102395A1 (en) * | 2018-06-04 | 2019-12-12 | Chemistryrx. | Topical compositions for stimulating hair growth |
-
2021
- 2021-11-16 MX MX2023005763A patent/MX2023005763A/es unknown
- 2021-11-16 WO PCT/US2021/059487 patent/WO2022108913A1/en active Application Filing
- 2021-11-16 US US17/527,688 patent/US20220152033A1/en not_active Abandoned
- 2021-11-16 IL IL302867A patent/IL302867A/en unknown
- 2021-11-16 WO PCT/US2021/059479 patent/WO2022108911A1/en active Application Filing
- 2021-11-16 US US18/037,316 patent/US20230414511A1/en active Pending
- 2021-11-16 CA CA3198046A patent/CA3198046A1/en active Pending
- 2021-11-16 MX MX2023005759A patent/MX2023005759A/es unknown
- 2021-11-16 EP EP21824185.9A patent/EP4247491A1/en active Pending
- 2021-11-16 US US17/527,856 patent/US11628177B2/en active Active
- 2021-11-16 AU AU2021381899A patent/AU2021381899A1/en active Pending
- 2021-11-16 JP JP2023529062A patent/JP2023550364A/ja active Pending
- 2021-11-16 IL IL302861A patent/IL302861A/en unknown
- 2021-11-16 KR KR1020237020504A patent/KR20230144002A/ko active Pending
- 2021-11-16 KR KR1020237020505A patent/KR20230142449A/ko active Pending
- 2021-11-16 AU AU2021383606A patent/AU2021383606A1/en active Pending
- 2021-11-16 JP JP2023529059A patent/JP7609994B2/ja active Active
- 2021-11-16 EP EP21824187.5A patent/EP4247336A1/en active Pending
- 2021-11-16 CA CA3197815A patent/CA3197815A1/en active Pending
-
2023
- 2023-03-22 US US18/124,906 patent/US12053481B2/en active Active
-
2024
- 2024-07-29 US US18/787,360 patent/US20240382502A1/en active Pending
- 2024-12-19 JP JP2024223773A patent/JP2025041743A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023550363A (ja) | 2023-12-01 |
| US20240382502A1 (en) | 2024-11-21 |
| JP2025041743A (ja) | 2025-03-26 |
| MX2023005763A (es) | 2023-05-29 |
| AU2021383606A1 (en) | 2023-06-29 |
| US20230414511A1 (en) | 2023-12-28 |
| CA3198046A1 (en) | 2022-05-27 |
| EP4247336A1 (en) | 2023-09-27 |
| JP7609994B2 (ja) | 2025-01-07 |
| JP2023550364A (ja) | 2023-12-01 |
| US11628177B2 (en) | 2023-04-18 |
| CA3197815A1 (en) | 2022-05-27 |
| KR20230144002A (ko) | 2023-10-13 |
| US20220152033A1 (en) | 2022-05-19 |
| WO2022108911A1 (en) | 2022-05-27 |
| US12053481B2 (en) | 2024-08-06 |
| IL302867A (en) | 2023-07-01 |
| WO2022108913A1 (en) | 2022-05-27 |
| IL302861A (en) | 2023-07-01 |
| US20230226083A1 (en) | 2023-07-20 |
| EP4247491A1 (en) | 2023-09-27 |
| US20220152061A1 (en) | 2022-05-19 |
| AU2021381899A1 (en) | 2023-07-06 |
| KR20230142449A (ko) | 2023-10-11 |
| AU2021383606A9 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005759A (es) | Composiciones y metodos para suministro de farmaco dermico profundo. | |
| GB0814302D0 (en) | Compounds and methods | |
| PH12020550341A1 (en) | Niraparib formulations | |
| MXPA05010565A (es) | Sistemas de suminsitro de farmacos que comprenden un ingrediente activo encapsulado. | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| MY140576A (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
| MXPA04007980A (es) | Preparado farmaceutico de sabor enmascarado en forma de pelicula o de oblea. | |
| BR0108730A (pt) | Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados | |
| WO2007022090A3 (en) | Topical delivery with a carrier fluid | |
| WO2005044226A3 (en) | Lipid formulations for spontaneous drug encapsulation | |
| HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
| MY144021A (en) | Pharmaceutical delivery system | |
| MY175781A (en) | Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation | |
| UA92498C2 (ru) | Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм | |
| JP2016505050A5 (es) | ||
| US3932624A (en) | Method for prolonging the inhibitory effect of saralasin on angiotensin II | |
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
| EA202191130A1 (ru) | Фармацевтическая композиция для лечения апластической анемии | |
| MX2024013213A (es) | Formulaciones de endoxifeno en dosis altas y metodos de uso | |
| MX2023001572A (es) | Formas farmaceuticas sólidas de palbociclib. | |
| WO2011014009A3 (ko) | 신규 이치환된 페녹시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물 | |
| EP4556025A3 (en) | Formulations of docetaxel | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| MX2024005738A (es) | Composiciones farmacéuticas de espironolactona para la administración dérmica profunda de fármacos. |